Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ICRF 154

Known as: ICRF-154 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
After the identification of a new lead bisphenol compound that had good topoisomerase IIα (EC 5.99.1.3) inhibitory activity, a… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2006
2006
Based on the topoisomerase IIα catalytic inhibitory activity of a previous hit compound, NSC35866, we screened 40 substituted… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
2000
2000
This study investigates the solution thermodynamics of the iron complexes of dexrazoxane (ICRF-187, (+)-1,2-bis(3,5… Expand
1997
1997
A Chinese hamster ovary (CHO) cell line highly resistant to the non-cleavable complex-forming topoisomerase II inhibitor… Expand
1997
1997
Histologic and biochemical studies were carried out to compare the protective activity of various bisdiketopiperazines against… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1995
Highly Cited
1995
A series of twelve structurally related bisdioxopiperazines that included ICRF-187 (dexrazoxane), ICRF-159 (razoxane), ICRF-193… Expand
1992
1992
We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1991
Highly Cited
1991
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1991
Highly Cited
1991
In the accompanying paper (K. Tanabe, Y. Ikegami, R. Ishida, and T. Andoh, Cancer Res., 51: 4903-4908, 1991), we showed that ICRF… Expand